Neurocrine Biosciences (NBIX) Net Equity Issued and Repurchased (2010 - 2026)

Neurocrine Biosciences has reported Net Equity Issued and Repurchased for 17 years, with the latest figure at $84.8 million in Q2 2026.

• Net Equity Issued and Repurchased for Q2 2026 came in at $84.8 million, up 488.89% year-over-year; the trailing twelve-month figure through Jun 2026 was $191.3 million (up 130.76% YoY), and the FY2025 annual result was $129.4 million, up 5.98% from the prior year.
• Net Equity Issued and Repurchased rose to $84.8 million in Q2 2026, from $23.6 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $84.8 million in Q2 2026 and troughed at $2.6 million in Q2 2022.
• A 5-year average of $26.1 million and a median of $21.2 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
• The widest annual swing landed in 2022, when Net Equity Issued and Repurchased jumped 1266.67%; it then plunged 71.75% in 2024.
• A 5-year view of Net Equity Issued and Repurchased shows it stood at $24.6 million in 2022, then soared by 43.9% to $35.4 million in 2023, then sank by 71.75% to $10.0 million in 2024, then soared by 273.0% to $37.3 million in 2025, then surged by 127.35% to $84.8 million in 2026.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $84.8 million in Q2 2026, $23.6 million in Q1 2026, and $37.3 million in Q4 2025.